Aimed Alliance Comments on 2027 NBPP
On March 13, 2026, Aimed Alliance commented on the 2027 Notice of Benefit and Payment Parameters (2027 NBPP). In its…
Browsing: Drug Pricing: Policy Activity
Aimed Alliance Provides Testimony of UPLs Before New Jersey’s PDAC
On March 19, 2026, Aimed Alliance provided testimony to the New Jersey Prescription Drug Affordability Council, which is developing legislative…
Aimed Alliance Submits Comment on FTC’s Proposed Settlement with Express Scripts
On March 16, Aimed Alliance submitted a comment on the proposed settlement between the Federal Trade Commission and Express Scripts,…
Aimed Alliance Pushes Back on PDAB Legislation in Illinois
On March 18, 2026, Aimed Alliance submitted comments to the Health Care Availability & Accessibility Committee urging caution against Illinois…
Aimed Alliance Urges Amendments to Virginia’s PDAB Bill to Protect Patient Access
On March 13, 2026, Aimed Alliance sent a letter to Governor Abigail Spanberger urging amendments to Virginia’s House Bill 483,…
Administration Targets Foreign Drug Pricing in Upcoming Section 301 Investigation
Recently, the Trump Administration announced plans to initiate a new Section 301 investigation into foreign drug pricing policies, which it…
Aimed Alliance Publishes Updated 2025 PDAB Resources
Aimed Alliance is pleased to share two new resources on prescription drug affordability boards (PDABs). PDABs are established at the…
Aimed Alliance Publishes New Resource on the USTR and MFN
Aimed Alliance has released a new fact sheet explaining the role of the U.S. Trade Representative (USTR) in shaping international…
CMS Launches GENEROUS Model to Lower Medicaid Drug Costs and Expand Access
Earlier this month, the Centers for Medicare & Medicaid Services (CMS) announced a new drug payment initiative aimed at addressing…
Aimed Alliance Releases New Explainer on 340B Program
On October 22, Aimed Alliance published a new resource on the 340B Drug Pricing Program (340B Program). The 340B program…